For example, checkpoint inhibition is considered as a first line therapy in non-small cell lung cancer if greater than 50% of tumour cells demonstrate membranous PD-L1 labelling [50], while for urothelial carcinoma both the presence of immune cells in the tumour and the percentage of immune cells with positive PD-L1 labelling inform the decision to treat with immunotherapy [51]. This evidence concerns the gene CD274 and urothelial carcinoma.